NASDAQ:AURA Aura Biosciences (AURA) Stock Price, News & Analysis $6.74 -0.15 (-2.18%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$6.74 0.00 (0.00%) As of 08/1/2025 05:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aura Biosciences Stock (NASDAQ:AURA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Aura Biosciences alerts:Sign Up Key Stats Today's Range$6.63▼$6.8750-Day Range$5.84▼$7.2352-Week Range$4.34▼$12.38Volume200,596 shsAverage Volume154,595 shsMarket Capitalization$338.82 millionP/E RatioN/ADividend YieldN/APrice Target$22.00Consensus RatingBuy Company Overview Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts. Read More Aura Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreAURA MarketRank™: Aura Biosciences scored higher than 31% of companies evaluated by MarketBeat, and ranked 769th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingAura Biosciences has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAura Biosciences has only been the subject of 2 research reports in the past 90 days.Read more about Aura Biosciences' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Aura Biosciences are expected to decrease in the coming year, from ($1.66) to ($2.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aura Biosciences is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aura Biosciences is -3.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAura Biosciences has a P/B Ratio of 2.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Aura Biosciences' valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted5.82% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Aura Biosciences has recently increased by 1.50%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAura Biosciences does not currently pay a dividend.Dividend GrowthAura Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted5.82% of the float of Aura Biosciences has been sold short.Short Interest Ratio / Days to CoverAura Biosciences has a short interest ratio ("days to cover") of 12.8, which indicates bearish sentiment.Change versus previous monthShort interest in Aura Biosciences has recently increased by 1.50%, indicating that investor sentiment is decreasing. News and Social Media0.6 / 5News SentimentN/A Search Interest4 people have searched for AURA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Aura Biosciences to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Aura Biosciences insiders have bought 4,284.51% more of their company's stock than they have sold. Specifically, they have bought $343,000.00 in company stock and sold $7,823.00 in company stock.Percentage Held by InsidersOnly 5.40% of the stock of Aura Biosciences is held by insiders.Percentage Held by Institutions96.75% of the stock of Aura Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aura Biosciences' insider trading history. Receive AURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aura Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address AURA Stock News HeadlinesAura Biosciences, Inc. (NASDAQ:AURA) Given Average Rating of "Buy" by AnalystsJuly 25, 2025 | americanbankingnews.comClearside Biomedical shares dip after announcing exploration of strategic alternativesJuly 17, 2025 | msn.comElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social Security? What we just discovered in Washington will stun even the most seasoned insiders.August 2 at 2:00 AM | Banyan Hill Publishing (Ad)JMP maintains $19 target on Aura Biosciences stock after FDA insightsMay 24, 2025 | uk.investing.comAura Biosciences Raises $69.9 Million in Public OfferingMay 16, 2025 | tipranks.comAura Biosciences Names Anthony Gibney Chief Financial, Business OfficerMay 16, 2025 | marketwatch.comAura Biosciences Announces Pricing of Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comAura Biosciences Announces Proposed Public Offering of Common Stock and WarrantsMay 15, 2025 | globenewswire.comSee More Headlines AURA Stock Analysis - Frequently Asked Questions How have AURA shares performed this year? Aura Biosciences' stock was trading at $8.22 on January 1st, 2025. Since then, AURA shares have decreased by 18.0% and is now trading at $6.74. How were Aura Biosciences' earnings last quarter? Aura Biosciences, Inc. (NASDAQ:AURA) released its quarterly earnings data on Thursday, May, 15th. The company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.47) by $0.08. When did Aura Biosciences IPO? Aura Biosciences (AURA) raised $81 million in an initial public offering (IPO) on Friday, October 29th 2021. The company issued 5,400,000 shares at $14.00-$16.00 per share. Who are Aura Biosciences' major shareholders? Aura Biosciences' top institutional investors include Regency Capital Management Inc. DE (1.32%), Platinum Investment Management Ltd. (0.27%), Harbor Capital Advisors Inc. (0.07%) and Ascent Group LLC (0.03%). Insiders that own company stock include Matrix Capital Management Comp, Los Pinos Elisabet De, Janet Jill Hopkins, Mark Plavsic, Conor Kilroy, David Michael Johnson, Julie B Feder, Amy Elazzouzi, Anthony S Gibney, Cadmus Rich and Rosch Mark De. View institutional ownership trends. How do I buy shares of Aura Biosciences? Shares of AURA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aura Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aura Biosciences investors own include Invesco QQQ (QQQ), SPDR S&P 500 ETF Trust (SPY), SPDR Dow Jones Industrial Average ETF Trust (DIA), Meta Platforms (META), Tesla (TSLA), NVIDIA (NVDA) and Advanced Micro Devices (AMD). Company Calendar Last Earnings5/15/2025Today8/02/2025Next Earnings (Estimated)8/14/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AURA CIK1501796 Webwww.aurabiosciences.com Phone617-500-8864FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Aura Biosciences$22.00 High Price Target$24.00 Low Price Target$19.00 Potential Upside/Downside+226.4%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)($1.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$86.92 million Net MarginsN/A Pretax MarginN/A Return on Equity-58.63% Return on Assets-49.74% Debt Debt-to-Equity RatioN/A Current Ratio11.06 Quick Ratio11.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.04 per share Price / Book2.22Miscellaneous Outstanding Shares50,270,000Free Float47,554,000Market Cap$338.82 million OptionableNot Optionable Beta0.46 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:AURA) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredToo busy to trade? Good.Too busy to trade? That might be your edge. This after-hours strategy is built for people who don’t sit at ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aura Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aura Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.